histaminergic receptor Inhibitors
2 drugsAbout histaminergic receptor
Histaminergic receptors are a class of G protein-coupled receptors that bind histamine, mediating various physiological effects. They are involved in inflammation, neurotransmission, and gastric acid secretion.
Currently, there is no genetic evidence available to support histaminergic receptors as therapeutic targets. Further research is needed to explore their potential for drug development.
Two small molecule drugs, CLOZAPINE and VERSACLOZ, target histaminergic receptors and are approved for CNS indications. These drugs are marketed by Teva and Douglas Pharmaceuticals.
Top histaminergic receptor Drugs
The competitive landscape is limited, with only two companies, Teva and Douglas Pharmaceuticals, having approved drugs.
Low market concentration suggests potential for new entrants, but also indicates possible challenges in target validation.
histaminergic receptor Drug Modality Landscape
Modalities
Routes of Administration
histaminergic receptor is amenable to small molecule drugs, with oral options available for convenient dosing.
Explore opportunities to develop novel modalities like antibodies or biologics to differentiate from existing therapies.
histaminergic receptor Clinical Trials 25 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on histaminergic receptor. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 2 | 2 | 0 | 0 | 100% |
| Phase 3 | 4 | 1 | 2 | 1 | 33% |
| Phase 4 | 19 | 11 | 2 | 6 | 85% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
histaminergic receptor Drug Approval Timeline (1996 - 2013)
The first drug was approved in 1996 (CLOZAPINE), and the most recent in 2013 (VERSACLOZ), spanning 18 years.
Slow approval rate suggests a saturated market or challenges in developing new drugs for this target class.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 2 companies competing
- • Market share by company
Full Drug Portfolio
- • All 2 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 2-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 21 (1 company)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on histaminergic receptor. A trial counts if an approved drug acting on histaminergic receptor is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.